All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Iterum Therapeutics plc found a lifeline in the securities purchase agreement it made with an investors group for a $51.9 million private placement. The company plans to use that money to develop sulopenem, a penem anti-infective compound with oral and I.V. formulations.